~~<i id='461882DC74'><strike id='461882DC74'><tt id='461882DC74'><pre id='461882DC74'></pre></tt></strike></i>~~

Home» explore» leisure time

leisure time

author：leisure time 2025-10-02 06:02:09 Page View：58217

Damian Garde of STAT talks with Liisa Bayko of Evercore ISI and Jared Holz of Mizuho at STAT in NYC. — Damian Garde of STAT, left, talked with Liisa Bayko of Evercore ISI and Jared Holz of Mizuho about the GLP-1 weight loss market. Michelle C. Gevint for STAT

NEW YORK — Will the world actually soon spend $100 billion a year on the new obesity medicines?

Plenty of people in pharma and at the banks that invest in it seem to think so. Goldman Sachs, Barclays, BMO Capital Markets and Pfizer have all arrived at the glossy, cut-for-headline number for spending by around 2030.

Yet Jared Holz, a healthcare strategist at Mizuho, is skeptical.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： A Greenpeace activist is fined for crash
Next article： Wildfire smoke exposes gaps in outdoor worker protections

Wikipedia

Drug repurposing or repositioning? The language matters

AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

China sends large group of warplanes, navy ships towards Taiwan in forceful display

FILE-InthisfilephotoreleasedbytheTaiwanMinistryofNationalDefense,aChinesePeople'sLiberationArmyH-6bo

Supreme Court strikes down use of affirmative action

ActivistsdemonstratedastheSupremeCourtheardoralargumentsonapairofaffirmativeactioncasesinOctober2022

Will Ozempic

Wegovy,theobesitydrug,wasinescapableattheObesityWeekconferenceinDallas.ElaineChenDALLAS—HereatObesit